In terms of weight loss results, the Wegovy pill demonstrated an average weight loss of approximately 13.6% over 64 weeks in its Phase 3 trial, whilst Foundayo showed an average weight loss of approximately 11% over 72 weeks at the highest dose
Curious to hear how others view the role of real-world data and post-approval evidence in MedTech evolution
If full discontinuation proves unsuccessful after 8 weeks, PlexusDx offers alternative compounds (Tirzepatide, GLP-Squared dual-mechanism therapy) that may provide superior appetite control with lower doses or different mechanisms
Symptoms vary depending on the infection site but often include a persistent urge to urinate, a burning sensation during urination, cloudy or strong-smelling urine, and pelvic pain in women
Table 1 shows the most relevant studies on drugs used in the treatment of MALSD
Women with PCOS or postmenopausal metabolic changes may have particular theoretical interest in retatrutide, though no sex-specific or condition-specific trials have been published
